問卷

TPIDB > Search Result

Search Result

篩選

List

55Cases

2023-12-01 - 2031-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2025-01-01 - 2029-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2025-01-21 - 2032-12-31

Phase I/II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2025-11-03

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2025-10-31 - 2029-02-04

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
Innovative Trial Interventional Therapies and Combinations for Colorectal Cancer: Key Program for Participants
  • Condition/Disease

    Colorectal cancer

  • Test Drug

    MEDI5752

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2029-03-01

Phase III

Active
A randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial evaluating the efficacy and safety of Ropeginterferon alfa-2b (P1101) in adult patients with pre-fibrotic/early primary myelofibrosis or marked primary myelofibrosis classified as low- or intermediate-risk 1 according to DIPSS Plus (HOPE-PMF): core trial and its extension trial.
  • Condition/Disease

    Clinically relevant complete hematologic response (CrCHR) at week 80, and symptom assessment indicators at week 80. CrCHR was defined as: 1. Platelet count ≤ 400 x 10^9/L, and 2. White blood cell (WBC) ≤ 10 x 10^9/L, and 3. Peripheral blood: Heme (Hgb) ≥ 10.0 g/dL, and 4. No major thrombotic events, and 5. No progression to secondary acute myeloid leukemia (AML). Symptom assessment indicators were defined as: 6. No worsening of clinical symptoms according to the MFSAF Total Symptom Score (TSS) version 4.0; no worsening of clinical symptoms was defined as: - If the baseline TSS score ≤ 10, then the TSS score remained ≤ 10; or - If the baseline TSS score > 10, then the TSS score did not increase by > 50%.

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
14Sites

Recruiting14Sites